Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrotinib + trastuzumab + aromatase inhibitor (Hengrui Therapeutics)
- Development stage
- Unknown
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Pyrotinib is an orally active, irreversible pan-ErbB receptor tyrosine kinase inhibitor that targets EGFR (HER1), HER2, and HER4. Developed by Jiangsu Hengrui Pharmaceuticals, it is approved in China for the treatment of HER2-positive metastatic breast cancer. This specific combination therapy, being evaluated in a Phase II trial sponsored by Peking Union Medical College Hospital, involves the administration of pyrotinib alongside trastuzumab (a HER2-targeted monoclonal antibody) and an aromatase inhibitor (such as anastrozole, letrozole, or exemestane). The regimen is intended for the first-line treatment of patients with HER2-positive and hormone receptor (HR)-positive metastatic or inoperable locally advanced breast cancer, aiming to provide a comprehensive blockade of both the HER2 and estrogen receptor signaling pathways.
- Brand names
- AiRuiNi
- Other names
- Pyrotinib maleate
02
Targets
CYP19A1 (Aromatase)EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on pyrotinib + trastuzumab + aromatase inhibitor (Hengrui Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrotinib + trastuzumab + aromatase inhibitor (Hengrui Therapeutics).